Showing results (141-150 of 182) with videos related to
Sort By:
Pageof 19
The Open Virology Journal|January 19, 2012
Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008Frederika Dijkstra, Marcel Jonges, Ruud van Beek, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2009
HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapyHans S L M Nottet, Sabine J van Dijk, Ewout B Fanoy, et al.AIDS (London, England)|August 8, 2013
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling studyBrooke E Nichols, Kim C E Sigaloff, Cissy Kityo, et al.AIDS (London, England)|August 14, 2013
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical modelsDavid A M C van de Vijver, Brooke E Nichols, Ume L Abbas, et al.AIDS Research and Human Retroviruses|September 14, 2017
A Summary of the Second Annual HIV Microbiome WorkshopBrett Williams, Mimi Ghosh, Charles A B Boucher, et al.Journal of the International AIDS Society|December 11, 2014
Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling studyBrooke E Nichols, Kim C E Sigaloff, Cissy Kityo, et al.Hepatology (Baltimore, Md.)|August 5, 2010
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levelsVincent Rijckborst, Bettina E Hansen, Yilmaz Cakaloglu, et al.Antiviral Therapy|May 11, 2011
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patientsJonathan M Schapiro, Charles A B Boucher, Daniel R Kuritzkes, et al.Journal of Virus Eradication|June 18, 2021
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure ConsortiumC Rokx, H A B Prins, L Vandekerckhove, et al.Plos Pathogens|October 3, 2012
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysisErhard van der Vries, Patrick J Collins, Sebastien G Vachieri, et al.Pageof 19